DK0701450T3 - Rekombinante viruser og deres anvendelse ved genterapi - Google Patents

Rekombinante viruser og deres anvendelse ved genterapi

Info

Publication number
DK0701450T3
DK0701450T3 DK94913650T DK94913650T DK0701450T3 DK 0701450 T3 DK0701450 T3 DK 0701450T3 DK 94913650 T DK94913650 T DK 94913650T DK 94913650 T DK94913650 T DK 94913650T DK 0701450 T3 DK0701450 T3 DK 0701450T3
Authority
DK
Denmark
Prior art keywords
pct
gene therapy
recombinant viruses
sec
date
Prior art date
Application number
DK94913650T
Other languages
Danish (da)
English (en)
Inventor
Patrick Benoit
Patrice Denefle
Michel Perricaudet
Sandrine Seguret
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of DK0701450T3 publication Critical patent/DK0701450T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94913650T 1993-04-30 1994-04-15 Rekombinante viruser og deres anvendelse ved genterapi DK0701450T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9305125A FR2704556B1 (fr) 1993-04-30 1993-04-30 Virus recombinants et leur utilisation en thérapie génique.
PCT/FR1994/000422 WO1994025073A1 (fr) 1993-04-30 1994-04-15 Virus recombinants et leur utilisation en therapie genique

Publications (1)

Publication Number Publication Date
DK0701450T3 true DK0701450T3 (da) 1999-02-08

Family

ID=9446605

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94913650T DK0701450T3 (da) 1993-04-30 1994-04-15 Rekombinante viruser og deres anvendelse ved genterapi

Country Status (17)

Country Link
US (2) USRE38556E1 (de)
EP (1) EP0701450B1 (de)
JP (1) JPH08509373A (de)
KR (1) KR100330142B1 (de)
AT (1) ATE169503T1 (de)
AU (1) AU696199B2 (de)
BR (1) BR9406689A (de)
CA (1) CA2161679A1 (de)
DE (1) DE69412486T2 (de)
DK (1) DK0701450T3 (de)
ES (1) ES2120036T3 (de)
FI (1) FI955154A0 (de)
FR (1) FR2704556B1 (de)
GR (1) GR3027660T3 (de)
NO (1) NO954286D0 (de)
WO (1) WO1994025073A1 (de)
ZA (1) ZA942980B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
FR2731229B1 (fr) * 1995-03-02 1997-04-30 Rhone Poulenc Rorer Sa Therapie genique de l'atherosclerose par production de hdl par les lignees monocytaires
US5734699A (en) * 1995-05-04 1998-03-31 Interwave Communications International, Ltd. Cellular private branch exchanges
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
CZ326896A3 (cs) * 1996-11-07 1998-05-13 Milo Olomouc, A. S. Tuk se specifickými protisklerotickými účinky
FR2755699B1 (fr) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
ATE291080T1 (de) 1996-12-06 2005-04-15 Aventis Pharma Inc Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
EP2343317A1 (de) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein-konstrukte
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) * 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
EP1453536A4 (de) * 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Zusammensetzung zur konservierung von viren
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
JP2007518423A (ja) * 2004-01-23 2007-07-12 イントロン、インコーポレイテッド スプライセオソーム仲介型ｒｎａトランススプライシングを使用するアポａ−１及びその変異体の発現
CA2602946A1 (en) * 2005-03-22 2006-09-28 Medstar Health, Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
US20100035974A1 (en) * 2006-10-04 2010-02-11 Centre National De La Recherche Scientifique (Cnrs Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61135587A (ja) * 1984-12-03 1986-06-23 Norin Suisansyo Shokuhin Sogo Kenkyusho アポリポタン白質ｅ遺伝子およびその調製法
ATE89314T1 (de) * 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
JPS63237795A (ja) * 1987-03-24 1988-10-04 Otsuka Pharmaceut Factory Inc アポリポタンパク質の製造法
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
FR2666813A1 (fr) * 1990-09-18 1992-03-20 Rhone Poulenc Sante Procede microbiologique de preparation de l'apolipoproteine aiv humaine ou de derives de celle-ci.
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
JP3534749B2 (ja) * 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6777977B1 (en) * 2002-05-01 2004-08-17 Actel Corporation Three input field programmable gate array logic circuit configurable as a three input look up table, a D-latch or a D flip-flop
CA2419216C (en) * 2003-02-19 2005-03-01 Jan Nyquist Method and apparatus for joining plastic pipe

Also Published As

Publication number Publication date
NO954286L (no) 1995-10-26
FI955154A7 (fi) 1995-10-27
FR2704556B1 (fr) 1995-07-13
EP0701450B1 (de) 1998-08-12
ZA942980B (en) 1995-01-18
FI955154L (fi) 1995-10-27
BR9406689A (pt) 1996-01-30
GR3027660T3 (en) 1998-11-30
AU6572294A (en) 1994-11-21
CA2161679A1 (fr) 1994-11-10
WO1994025073A1 (fr) 1994-11-10
DE69412486T2 (de) 1999-03-11
FR2704556A1 (fr) 1994-11-04
KR100330142B1 (ko) 2002-09-27
US5866551A (en) 1999-02-02
USRE38556E1 (en) 2004-07-13
FI955154A0 (fi) 1995-10-27
JPH08509373A (ja) 1996-10-08
ATE169503T1 (de) 1998-08-15
NO954286D0 (no) 1995-10-26
DE69412486D1 (de) 1998-09-17
AU696199B2 (en) 1998-09-03
ES2120036T3 (es) 1998-10-16
EP0701450A1 (de) 1996-03-20

Similar Documents

Publication Publication Date Title
DK0701450T3 (da) Rekombinante viruser og deres anvendelse ved genterapi
DK0698108T3 (da) Adenovirale vektorer af animalsk oprindelse og deres anvendelse ved genterapi
NO953187L (no) Imidazopyridiner og deres anvendelse ved behandling av mave-tarm-sykdommer
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ZA943744B (en) Therapeutic substituted guanidines
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
DK0663835T3 (da) Anvendelse af parathormon, dets biologisk aktive fragmenter og relaterede peptider til behandling af graviditet
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
FI960333A0 (fi) Tryptaasi-inhibiittori
EP0760013A4 (de) Behandlung von influenzavirusinfektion mittels antivirale verbindungen, welche die acylierung/palmitylierung von hemagglutinin inhibieren
BR0009666A (pt) Adenovìrus recombinante e mutante derivado de adenovìrus bovino tipo 1
ATE145135T1 (de) Verwendung von riluzol zum schutz gegen strahlenschäden